Publications by authors named "J Fredriksson"
Article Synopsis
- The Comet Interceptor mission aims to explore a long-period comet or an interstellar object entering our Solar System, with a focus on its surface composition, shape, and the composition of its gas and dust.
- Proposed to the European Space Agency in 2018 and approved in June 2022, it is set to launch in 2029 alongside the Ariel mission, utilizing a low-cost approach that allows it to wait for a suitable target comet.
- The mission will feature a main probe and two sub-probes (B1 from JAXA and B2), providing simultaneous, detailed 3D information about the comet and its interaction with the solar wind, making it unique compared to previous missions.
GRK2 selectively attenuates the neutrophil NADPH-oxidase response triggered by β-arrestin recruiting GPR84 agonists.
Biochim Biophys Acta Mol Cell Res
July 2022
In order to avoid a prolonged pro-inflammatory neutrophil response, signaling downstream of an agonist-activated G protein-coupled receptor (GPCR) has to be rapidly terminated. Among the family of GPCR kinases (GRKs) that regulate receptor phosphorylation and signaling termination, GRK2, which is highly expressed by immune cells, plays an important role. The medium chain fatty acid receptor GPR84 as well as formyl peptide receptor 2 (FPR2), receptors expressed in neutrophils, play a key role in regulating inflammation.
View Article and Find Full Text PDFHighly pathogenic strains produce phenol-soluble modulins (PSMs), which are -formylated peptides. Nanomolar concentrations of PSMα2 are recognized by formyl peptide receptor 2 (FPR2), but unlike the prototypic FPR2 agonist WKYMVM, PSMα2 is a biased signaling agonist. The truncated N-terminal PSMα2 variant, consisting of the five N-terminal residues, is no longer recognized by FPR2, showing that the C-terminal part of PSMα2 confers FPR2 selectivity, whereas the N-terminal part may interact with the FPR1 binding site.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to evaluate patient preferences for a fixed-dose combination treatment of pertuzumab and trastuzumab given as a subcutaneous injection in patients with HER2-positive early breast cancer.
- Out of 160 patients, 136 (85%) preferred subcutaneous (SC) administration due to factors like reduced clinic time and comfort, with 88% being satisfied with the SC method compared to 67.5% for intravenous (IV) infusion.
- The findings suggest that subcutaneous administration is generally well tolerated, offers significant time savings, and presents no new safety concerns compared to the standard IV method.
Treatment of patients with cancer in hospitals or clinics is resource-intensive and imposes a burden on patients. 'Flexible care' is a term that can be used to describe treatment administered outside the oncology ward, oncological outpatient clinic or office-based oncologist setting. Programmes that reduce travel burden by bringing cancer treatment to the patient's home, workplace or closer to the patient's home, in the form of satellite clinics or mobile cancer units, expand treatment capacity and are well received.
View Article and Find Full Text PDF